RE:ManagementWe are into July, with the first half of 2021 done with no significant updates other than the Boston investment. Timelines is really what these people suck at. Being lazy is one thing, but they just don't get the work done and simply provide excuses for years and not even admitting clearly that they failed with their timelines again. You bring up a great recent example which is the serology test where they prepared a nice slide in the corporate update stating that revenues are expected into q4 2020 and early 2021. We don't even know if the test is approved. I am holding all my shares and adding more when I get a chance now that aducanumab is approved, however the SP still sitting at 21 cents shows the low level of confidence investors have with how slow things are with PMN. I know nothing happens overnight in the pharma world and it's a long boring wait but I have been holding this stock for years and I have seen many timelines come and go with nothing great to put on table. I remember over five years ago they were talking about a partner for progressing PMN310 and they still have nothing to show.
Thenorth1990 wrote: The guys on top are there for a reason, there is no point bashing them every now and then. For me personally their success was getting the guys from Boston before the biogen Judegment day and the gamble to align ourselves with aducanumab kind of paid off. I do hate the fact that they don't stick to the timeliness they provide and thankfully they have the forward looking statement disclosure to hide behind. -Waiting for an update on Serology , probably the most disappointing work yet by promis. We were all told that this would be ready by last summer and expected revenues q4 2020. I hope we had some way of keeping them accountable. We all know this has potential and now it's been validated. When this happens it will be huge for sure, but my hopes for some sp action happening this quarter is dead. Happy Weekend